BeiGene
BGNE
#961
Rank
HK$157.34 B
Marketcap
HK$1,438
Share price
0.49%
Change (1 day)
9.56%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of September 2024 : HK$8.57 Billion

According to BeiGene 's latest financial reports the company's total debt is HK$8.57 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31HK$7.26 B55.83%
2022-12-31HK$4.66 B-13.93%
2021-12-31HK$5.41 B24.33%
2020-12-31HK$4.35 B101.69%
2019-12-31HK$2.15 B39.03%
2018-12-31HK$1.55 B20.73%
2017-12-31HK$1.28 B860.17%
2016-12-31HK$0.13 B-16.81%
2015-12-31HK$0.16 B50.1%
2014-12-31HK$0.10 B-49.42%
2013-12-31HK$0.21 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
HK$3.98 B-53.49%๐Ÿ‡บ๐Ÿ‡ธ USA